efanesoctocog alfa
Jump to navigation
Jump to search
Indications
- first ultra-long 1/2 life factor VIII agent that enables once weekly prophylaxis for patients with severe hemophilia A.
Notes
- some concern regarding socot effectiveness[1]
More general terms
References
- ↑ 1.0 1.1 Ito S et al Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in People Living With Severe Hemophilia A: A Cost-Effectiveness Analysis. Ann Intern Med. 2025. April 22. PMID: https://pubmed.ncbi.nlm.nih.gov/40258278 https://www.acpjournals.org/doi/10.7326/ANNALS-24-02749